US2014303125A1PendingUtilityA1

Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency

Assignee: GRUENENTHAL GMBHPriority: Apr 11, 2005Filed: Jun 20, 2014Published: Oct 9, 2014
Est. expiryApr 11, 2025(expired)· nominal 20-yr term from priority
A61P 25/30A61P 25/36A61P 25/00A61K 31/407A61K 31/137A61K 31/438A61K 31/485A61K 45/06
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Spirocyclic cyclohexane compounds useful in pharmaceutical compositions for use in the treatment of substance dependency.

Claims

exact text as granted — not AI-modified
1 - 22 . (canceled) 
     
     
         23 . A method of treating opioid dependency in a patient, said method comprising administering to said patient an effective amount of 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole in the form of a pure stereoisomer or a mixture of stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof. 
     
     
         24 . The method according to  claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole or the physiologically acceptable salt thereof is in the form of a pure enantiomer or diastereomer. 
     
     
         25 . The method according to  claim 23 , wherein the 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole or the physiologically acceptable salt thereof is in the form of a racemate. 
     
     
         26 . The method according to  claim 23 , wherein the opioid dependency is heroin, morphine or methadone dependency. 
     
     
         27 . The method according to  claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is used in combination with naloxone. 
     
     
         28 . The method according to  claim 23 , wherein the 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is present in the form of its hydrochloride, citrate, methane sulfonate or hemicitrate. 
     
     
         29 . The method according to  claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is used in the form of the free base. 
     
     
         30 . The method according to  claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is present in the form of the non-polar diastereomer. 
     
     
         31 . The method according to  claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is present in the form of the non-polar diastereomer of the free base. 
     
     
         32 . The method according to  claim 23 , wherein 1,1-(3-dimethylamino-3-phenylpenta-methylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole is present in the form of the non-polar diastereomer of the free base and the opioid dependency is heroin, morphine or methadone dependency.

Join the waitlist — get patent alerts

Track US2014303125A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.